Tarceva receives approval for pancreatic cancer in the US
Saturday, November 05, 2005 09:00 IST Basel
Tarceva (erlotinib), the only EGFR-inhibitor to have shown a survival benefit in lung cancer, will now benefit patients with advanced pancreatic cancer following FDA approval in the United States